drugset / Trial / NCT02899286
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of PEG-BCT-100 in patients with relapsed or refractory acute myeloid leukemia (AML) in terms of remission rate.
Timeline
- Start
- 2016-09
- Primary completion
- 2019-09
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEG-BCT-100 | Protein / enzyme biologic | 1600 iu/kg | Intravenous |
| Subject | PEG-BCT-100 | Protein / enzyme biologic | 2500 iu/kg | Intravenous |